XML 16 R4.htm IDEA: XBRL DOCUMENT v3.8.0.1
Condensed Consolidated Statements of Operations - USD ($)
shares in Millions, $ in Millions
 3 Months Ended
Sep. 30, 2017
Sep. 30, 2016
Income Statement [Abstract]    
Molecular diagnostic testing $ 178.8 $ 165.1
Pharmaceutical and clinical services 11.4 12.4
Total revenue 190.2 177.5
Costs and expenses:    
Cost of molecular diagnostic testing 36.2 34.3
Cost of pharmaceutical and clinical services 6.8 5.7
Research and development expense 17.8 19.4
Change in the fair value of contingent consideration (73.2) 0.5
Selling, general, and administrative expense 115.2 111.9
Total costs and expenses 102.8 171.8
Operating income 87.4 5.7
Other income (expense):    
Interest income 0.4 0.3
Interest expense (0.9) (0.7)
Other (0.3) (1.3)
Total other income (expense): (0.8) (1.7)
Income before income tax 86.6 4.0
Income tax provision 5.6 5.2
Net income (loss) 81.0 (1.2)
Net loss attributable to non-controlling interest (0.1)  
Net income (loss) attributable to Myriad Genetics, Inc. stockholders $ 81.1 $ (1.2)
Earnings per share:    
Basic $ 1.18 $ (0.02)
Diluted $ 1.15 $ (0.02)
Weighted average shares outstanding:    
Basic 68.6 68.8
Diluted 70.4 68.8